Scholar Rock Holding Corporation · Q2 2021 earnings

Briefing

Scholar Rock reported financial results for the second quarter ended June 30, 2021.

Scholar Rock reported a net loss of $30.7 million, or $0.84 per share, and revenue of $4.6 million for the quarter ended June 30, 2021. The company's cash and cash equivalents totaled approximately $282 million at the end of the quarter.

• Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA) anticipated to initiate by end of 2021.
• DRAGON Phase 1 trial evaluating SRK-181’s ability to overcome resistance to checkpoint inhibitors continues to progress and on-track to advance to Part B dose expansion mid-year 2021
• Positive top-line data from the TOPAZ Phase 2 trial were presented, showing meaningful motor function improvements with apitegromab in SMA patients.
• The FDA granted Fast Track designation for apitegromab for the treatment of patients with Spinal Muscular Atrophy.

Headline financials

Revenue & EPS history

Scholar Rock is working closely with regulatory authorities to finalize the design of the Phase 3 trial for apitegromab and to progress the DRAGON trial to Part B to evaluate SRK-181 across multiple tumor types.